Correction to Lancet Oncol 2017; 18: 1182–91 (S1470204517304229 (2017) 18(9) (1182–1191) (S1470204517304229) (10.1016/S1470-2045(17)30422-9));Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

The Lancet Oncology

Volumn 18, Issue 9, 2017, Pages 1182-1191

  Overman, Michael J ^a   McDermott, Ray ^b   Leach, Joseph L ^c   Lonardi, Sara ^d   Lenz, Heinz Josef ^e   Morse, Michael A ^f   Desai, Jayesh ^g   Hill, Andrew ^h   Axelson, Michael ⁱ   Moss, Rebecca A ⁱ   Goldberg, Monica V ⁱ   Cao, Z Alexander ⁱ   Ledeine, Jean Marie ⁱ   Maglinte, Gregory A ⁱ   Kopetz, Scott ^a   André, Thierry ^j  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c Allina Hospitals & Clinics   (United States)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h Tasman Oncology Research Ltd   (Australia)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; NIVOLUMAB; OXALIPLATIN; REGORAFENIB; TRIACYLGLYCEROL LIPASE; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT; ARTHRITIS; ARTICLE; ASTHENIA; AUSTRALIA; BELGIUM; CANADA; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; COLITIS; DEATH; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; DRY SKIN; DUODENUM ULCER; ESOPHAGITIS; ETHNICITY; FATIGUE; FEMALE; FEVER; FOLLOW UP; FRANCE; GASTRITIS; HOSPITAL; HUMAN; HYPOTHYROIDISM; IRELAND; ITALY; LYMPHOCYTE COUNT; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SIDE EFFECT; SPAIN; STOMATITIS; SUDDEN DEATH; TREATMENT DURATION; UNITED STATES; ANTAGONISTS AND INHIBITORS; CARCINOMA; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SECONDARY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MISMATCH REPAIR; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 85025439295     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30638-1     Document Type: Erratum

References (33)

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed Jan 13, 2017).
2. NCCN Clinical Practice Guidelines in Oncology. Colon cancer. V2.2017. https://www.nccn.org/ (accessed July 7, 2017).
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: colon and rectum cancer. http://seer.cancer.gov/statfacts/html/colorect.html (accessed Jan 13, 2017).
4. Goldstein, J, Tran, B, Ensor, J, et al. Multicenter retrospective analysis of metastatic CRC with high-level microsatellite instability (MSI-H). Ann Oncol 25 (2014), 1032–1038.
5. Koopman, M, Kortman, GA, Mekenkamp, L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100 (2009), 266–273.
6. Venderbosch, S, Nagtegaal, ID, Maughan, TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20 (2014), 5322–5330.
7. Tran, B, Kopetz, S, Tie, J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117 (2011), 4623–4632.
8. Giannakis, M, Mu, XJ, Shukla, SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 15 (2016), 857–865.
9. Llosa, NJ, Cruise, M, Tam, A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5 (2015), 43–51.
10. Saeterdal, I, Bjørheim, J, Lislerud, K, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci USA 98 (2001), 13255–13260.
11. Schwitalle, Y, Kloor, M, Eiermann, S, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134 (2008), 988–997.
12. Le, DT, Uram, JN, Wang, H, et al. Programmed death-1 blockade in mismatch repair deficient colorectal cancer. J Clin Oncol, 34, 2016, 103.
13. Brahmer, J, Drake, C, Wollner, I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 (2010), 3167–3175.
14. Le, DT, Uram, JN, Wang, H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
15. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
16. Aaronson, NK, Ahmedzai, S, Bergman, B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
17. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16 (1990), 199–208.
18. Osoba, D, Rodrigues, G, Myles, J, Zee, B, Pater, J, Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998), 139–144.
19. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf, June 14, 2010 (accessed Jan 13, 2017).
20. Domingo, E, Niessen, RC, Oliveira, C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24 (2005), 3995–3998.
21. Yaeger, R, Saltz, L, BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy. J Natl Compr Canc Netw 10 (2012), 1456–1458.
22. Di Nicolantonio, F, Martini, M, Molinari, F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 (2008), 5705–5712.
23. De Roock, W, Claes, B, Bernasconi, D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11 (2010), 753–762.
24. Kopetz, S, McDonough, SL, Morris, VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol, 35, 2017, 520.
25. Corcoran, RB, André T, Yoshino, T, et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (metastatic colorectal cancer). Ann Oncol 27 (2016), 149–206.
26. Janssen, B, Szende, A, Population norms for the EQ-5D. Szende, A, Janssen, B, Cabases, J, (eds.) Self-reported population health: an international perspective based on EQ-5D, 2014, Springer, Dordrecht, the Netherlands, 19–30.
27. Antonia, SJ, López-Martin, JA, Bendell, J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17 (2016), 883–895.
28. Ferris, RL, Blumenschein, G Jr, Fayette, J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
29. Opdivo [package insert], 2016, Bristol-Myers Squibb Co, Princeton, NJ.
30. Andre, T, Lonardi, S, Wong, KYM, et al. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study. Proc Am Soc Clin Oncol, 35, 2017, 3531.
31. Sueda, T, Sakai, D, Kudo, T, et al. Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies. Anticancer Res 36 (2016), 4299–4306.
32. Grothey, A, Van Cutsem, E, Sobrero, A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
33. Mayer, RJ, Van Cutsem, E, Falcone, A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372 (2015), 1909–1919.